Base de dados : MEDLINE
Pesquisa : C23.888.821.712 [Categoria DeCS]
Referências encontradas : 14127 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1413 ir para página                         

  1 / 14127 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463865
[Au] Autor:Weant KA; Bailey AM; Baum RA; Justice SB; Calhoun CD
[Ad] Endereço:Pharmacy Services, Medical University of South Carolina, Charleston (Drs Weant and Calhoun); Department of Pharmacy Services, University of Kentucky HealthCare, Lexington (Drs Bailey and Baum); Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington (Drs Bailey and Baum); and Clinical Pharmacy Services, St. Claire Regional Medical Center, Morehead, Kentucky (Dr Justice).
[Ti] Título:Antiemetic Use in the Emergency Department.
[So] Source:Adv Emerg Nurs J;39(2):97-105, 2017 Apr/Jun.
[Is] ISSN:1931-4493
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting are 2 of the most common complaints of patients presenting to the emergency department (ED). In addition, antiemetics are the most commonly prescribed medications in the ED behind analgesics. Treating these conditions can be complex, especially as one considers that nausea and/or vomiting could be the primary presenting illness or simply a symptom of a more complex etiology. Although there is a wide variety of pharmacotherapeutic options in the armamentarium to treat these conditions, very few consensus recommendations exist to help guide the use of antiemetic agents in the ED, leading to wide variability in medication use. Contributing to these variations in practice is the extended spectrum of etiologies and potential physiological factors that contribute to the development of nausea or vomiting. A thorough understanding of the pharmacology and administration of these agents can help practitioners devise tailored antiemetic regimens based upon the underlying etiology.
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Serviço Hospitalar de Emergência
Náusea/prevenção & controle
Vômito/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/TME.0000000000000141


  2 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465577
[Au] Autor:Peng T; Hu Z; Yang X; Gao Y; Ma C
[Ad] Endereço:Department of Nephrology, Shandong University Qilu Hospital, Jinan City, China.
[Ti] Título:Nitrite-induced acute kidney injury with secondary hyperparathyroidism: Case report and literature review.
[So] Source:Medicine (Baltimore);97(8):e9889, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Acute kidney injury (AKI) with hyperparathyroidism caused by nitrite was rare, and renal function and parathyroid hormone (PTH) decreased to normal range after therapy. PATIENT CONCERNS: Acute kidney injury was diagnosed in a 40-year-old male with hyperparathyroidism and cyanosis of his hands and both forearms. DIAGNOSES: The patient ate some recently pickled vegetables, and he experienced nausea, vomiting and diarrhoea without oliguria or anuria; Additionally, his hands and both forearms had a typical blue ash appearance. After admission, the laboratory findings indicated theincreasing serum creatinine (Scr) and parathyroid hormone (PTH). He was diagnosed as acute kidney injury with hyperparathyroidism caused by nitrite. INTERVENTIONS: The patient stopped eating the pickled vegetables and was given rehydration, added calories and other supportive therapy without any glucocorticoids. OUTCOMES: According to his clinical manifestations, laboratory findings and imaging results, the patient was diagnosed with acute kidney injury with secondary hyperparathyroidism. He was given symptomatic supportive care therapy. After one week, the serum creatinine, parathyroid hormone (PTH), hypercalcemia, hyperphosphatemia, proteinuria, and urine red blood cell values decreased to normal range. LESSONS: Nitrite-induced acute kidney injury with secondary hyperparathyroidism was relatively rare. After therapy, the function of the kidney and parathyroid returned to normal. This case suggests that detailed collection of medical history, physical examination and correct symptomatic treatment is very important.
[Mh] Termos MeSH primário: Lesão Renal Aguda/induzido quimicamente
Hiperparatireoidismo Secundário/induzido quimicamente
Nitritos/envenenamento
[Mh] Termos MeSH secundário: Lesão Renal Aguda/terapia
Adulto
Cianose/induzido quimicamente
Diarreia/induzido quimicamente
Hidratação
Conservação de Alimentos
Seres Humanos
Hiperparatireoidismo Secundário/terapia
Masculino
Náusea/induzido quimicamente
Apoio Nutricional
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Nitrites)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009889


  3 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374715
[Au] Autor:Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
[Ad] Endereço:Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
[Ti] Título:Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
[So] Source:Anticancer Res;38(2):877-884, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Chemotherapy-induced nausea and vomiting (CINV) is one of most distressing adverse events during cancer chemotherapy. In breast cancer patients receiving anthracycline and cyclophosphamide (AC) chemotherapy, CINV is poorly controlled. PATIENTS AND METHODS: The prevalence of guideline-consistent antiemetic medication and control of CINV were investigated retrospectively in breast cancer patients receiving the first cycle of AC chemotherapy. Risks for CINV were analyzed by the multivariate logistic regression analysis. The effect of olanzapine added to the standard antiemetic medication on the incidence of CINV was subsequently evaluated in separate patients who received the first cycle of AC chemotherapy. RESULTS: Although the guideline-consistent antiemetic medication was performed in all subjects, the control rate of nausea (32%), but not vomiting (78%) was low. Risk analysis indicated that age younger than 55-year-old was a significant factor that reduces the control of both nausea and vomiting. Olanzapine (5 mg/day for 5 days), when added to the standard three-drug antiemetic medication, significantly improved the control of nausea and complete response. CONCLUSION: CINV was poorly controlled in breast cancer patients receiving AC chemotherapy, in which age younger than 55-year-old was a significant risk for both nausea and vomiting. Olanzapine was effective for improvement of the control of CINV associated with AC chemotherapy. Therefore, care should be taken to prevent CINV in young patients receiving AC chemotherapy by adding olanzapine to the standard three-drug antiemetic medication.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Benzodiazepinas/administração & dosagem
Neoplasias da Mama/tratamento farmacológico
Náusea/tratamento farmacológico
Vômito/tratamento farmacológico
[Mh] Termos MeSH secundário: Fatores Etários
Antraciclinas/administração & dosagem
Antraciclinas/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Feminino
Seres Humanos
Meia-Idade
Náusea/induzido quimicamente
Náusea/prevenção & controle
Estudos Retrospectivos
Vômito/induzido quimicamente
Vômito/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthracyclines); 0 (Antiemetics); 12794-10-4 (Benzodiazepines); 8N3DW7272P (Cyclophosphamide); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  4 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240363
[Au] Autor:Gezginci E; Yyigun E; Yalcin S; Ozgok IY
[Ti] Título:Symptoms Control for Patients with Superficial Bladder Cancers Before and After TURBT and Intravesical Epirubicin Instillation.
[So] Source:Urol Nurs;37(1):31-5, 2017 Jan-Feb.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bladder cancer is one of the most common cancers among urologic cancers. Intravesical instillation following transurethral resection of bladder tumor (TURBT) is used as a treatment of bladder cancer. According to results of this study, before and after intravesical instillations following TURBT have no effect on symptom outcomes of patients with superficial bladder cancer.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/administração & dosagem
Carcinoma de Células de Transição/terapia
Cistoscopia/métodos
Epirubicina/administração & dosagem
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Administração Intravesical
Adolescente
Adulto
Idoso
Ansiedade/epidemiologia
Carcinoma de Células de Transição/epidemiologia
Carcinoma de Células de Transição/patologia
Depressão/epidemiologia
Fadiga/epidemiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Náusea/epidemiologia
Invasividade Neoplásica
Dor Pós-Operatória/epidemiologia
Período Pós-Operatório
Avaliação de Sintomas
Turquia/epidemiologia
Neoplasias da Bexiga Urinária/epidemiologia
Neoplasias da Bexiga Urinária/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 3Z8479ZZ5X (Epirubicin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  5 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28468890
[Au] Autor:Yeung SE; Hilkewich L; Gillis C; Heine JA; Fenton TR
[Ad] Endereço:Nutrition Services and sophia.yeung@ahs.ca.
[Ti] Título:Protein intakes are associated with reduced length of stay: a comparison between Enhanced Recovery After Surgery (ERAS) and conventional care after elective colorectal surgery.
[So] Source:Am J Clin Nutr;106(1):44-51, 2017 Jul.
[Is] ISSN:1938-3207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Protein can modulate the surgical stress response and postoperative catabolism. Enhanced Recovery After Surgery (ERAS) protocols are evidence-based care bundles that reduce morbidity. In this study, we compared protein adequacy as well as energy intakes, gut function, clinical outcomes, and how well nutritional variables predict length of hospital stay (LOS) in patients receiving ERAS protocols and conventional care. We conducted a prospective cohort study in adult elective colorectal resection patients after conventional ( = 46) and ERAS ( = 69) care. Data collected included preoperative Malnutrition Screening Tool (MST) score, 3-d food records, postoperative nausea, LOS, and complications. Multivariable regression analysis assessed whether low protein intakes and the MST score were predictive of LOS. Total protein intakes were significantly higher in the ERAS group due to the inclusion of oral nutrition supplements (conventional group: 0.33 g · kg · d ; ERAS group: 0.54 g · kg · d ; < 0.02). This group difference in protein intake was maintained in a multivariable model that controlled for differences between baseline and surgical variables ( = 0.001). Oral food intake did not differ between the 2 groups. The ERAS group had shorter LOS ( = 0.049) and fewer total infectious complications ( = 0.01). Nausea was a predictor of protein intake. Nutrition variables were independent predictors of earlier discharge after potential confounders were controlled for. Each unit increase in preoperative MST score predicted longer LOSs of 2.5 d (95% CI: 1.5, 3.5 d; < 0.001), and the consumption of ≥60% of protein requirements during the first 3 d of hospitalization was associated with a shorter LOS of 4.4 d (95% CI: -6.8, -2.0 d; < 0.001). ERAS patients consumed more protein due to the inclusion of oral nutrition supplements. However, total protein intake remained inadequate to meet recommendations. Consumption of ≥60% protein needs after surgery and MST scores were independent predictors of LOS. This trial was registered at clinicaltrials.gov as NCT02940665.
[Mh] Termos MeSH primário: Neoplasias Colorretais/cirurgia
Proteínas na Dieta/administração & dosagem
Suplementos Nutricionais
Procedimentos Cirúrgicos do Sistema Digestório
Tempo de Internação
Estado Nutricional
Cuidados Pós-Operatórios/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Cirurgia Colorretal
Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos
Ingestão de Energia
Comportamento Alimentar
Seres Humanos
Intestino Grosso/cirurgia
Masculino
Meia-Idade
Náusea/etiologia
Necessidades Nutricionais
Assistência Perioperatória
Complicações Pós-Operatórias
Estudos Prospectivos
Padrão de Cuidado
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Proteins)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180121
[Lr] Data última revisão:
180121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170505
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.3945/ajcn.116.148619


  6 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266076
[Au] Autor:Committee on Practice Bulletins-Obstetrics
[Ti] Título:ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.
[So] Source:Obstet Gynecol;131(1):e15-e30, 2018 01.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting of pregnancy is a common condition that affects the health of a pregnant woman and her fetus. It can diminish a woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because morning sickness is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric care providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about the safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms. Treatment in the early stages may prevent more serious complications, including hospitalization (4). Safe and effective treatments are available for more severe cases, and mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. Nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Saúde Materna
Êmese Gravídica/prevenção & controle
Guias de Prática Clínica como Assunto
Primeiro Trimestre da Gravidez
[Mh] Termos MeSH secundário: Comitês Consultivos/normas
Antieméticos/farmacologia
Medicina Baseada em Evidências
Feminino
Seres Humanos
Êmese Gravídica/tratamento farmacológico
Náusea/tratamento farmacológico
Náusea/fisiopatologia
Obstetrícia/normas
Gravidez
Resultado da Gravidez
Índice de Gravidade de Doença
Estados Unidos
Vômito/tratamento farmacológico
Vômito/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002456


  7 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266070
[Ti] Título:ACOG Practice Bulletin No. 189 Summary: Nausea And Vomiting Of Pregnancy.
[So] Source:Obstet Gynecol;131(1):190-193, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting of pregnancy is a common condition that affects the health of a pregnant woman and her fetus. It can diminish a woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because morning sickness is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric care providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about the safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms. Treatment in the early stages may prevent more serious complications, including hospitalization (4). Safe and effective treatments are available for more severe cases, and mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. Nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Êmese Gravídica/diagnóstico
Êmese Gravídica/tratamento farmacológico
Guias de Prática Clínica como Assunto
Resultado da Gravidez
[Mh] Termos MeSH secundário: Comitês Consultivos
Medicina Baseada em Evidências
Feminino
Seres Humanos
Náusea/tratamento farmacológico
Náusea/fisiopatologia
Gravidez
Primeiro Trimestre da Gravidez
Medição de Risco
Índice de Gravidade de Doença
Estados Unidos
Vômito/tratamento farmacológico
Vômito/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002450


  8 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187462
[Au] Autor:Fujii H; Iihara H; Kajikawa N; Kobayashi R; Suzuki A; Tanaka Y; Yamaguchi K; Yoshida K; Itoh Y
[Ad] Endereço:Department of Pharmacy, Gifu University Hospital, Gifu, Japan h_fujii@gifu-u.ac.jp.
[Ti] Título:Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.
[So] Source:Anticancer Res;37(12):6831-6837, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cisplatin is commonly used for esophageal and gastric cancer, but has a high emetic risk. Although the control of vomiting is favorable, nausea is still poorly controlled in patients receiving cisplatin-based regimens. The present study was designed to determine the risks for cisplatin-induced nausea. The effect of olanzapine, an antipsychotic drug, as an antiemetic for patients with risk of poor control of nausea was subsequently examined. PATIENTS AND METHODS: The prevalence of antiemetic medication and the control of nausea and vomiting were retrospectively examined in patients with esophageal or gastric cancer receiving the first cycle of cisplatin-based chemotherapy. Risks for nausea were analyzed by multivariate logistic regression analysis, in which threshold for age and cisplatin dose wer assessed by receiver operating characteristic curve analysis. RESULTS: A total of 186 patients received cisplatin-based regimens during January 2011 and December 2016. Guideline-consistent antiemetic medication was administered to all patients. Although the rate of no vomiting was high (93%), the rate of non-significant (grade 2 or more) nausea was insufficient (64%) during the overall period. Risk analysis showed that cisplatin dose of 50 mg/m or more and female gender were significant risks for nausea. Addition of olanzapine, but not of prochlorperazine, to the standard antiemetic medication was effective in suppressing nausea in patients who experienced nausea in the first cycle. CONCLUSION: Being female and cisplatin doses at 50 mg/m or more were demonstrated to increase risk for nausea. Addition of olanzapine to the standard medication was effective in preventing nausea in high-risk patients with esophageal and gastric cancer.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Benzodiazepinas/uso terapêutico
Neoplasias Esofágicas/tratamento farmacológico
Náusea/prevenção & controle
Neoplasias Gástricas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antieméticos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Náusea/induzido quimicamente
Estudos Retrospectivos
Fatores de Risco
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 12794-10-4 (Benzodiazepines); N7U69T4SZR (olanzapine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  9 / 14127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187487
[Au] Autor:Caivano D; Valeriani M; Russo I; Bonome P; DE Matteis S; Minniti G; Osti MF
[Ad] Endereço:CNAO, National Centre of Oncological Hadrontherapy, Pavia, Italy donatella.caivano@gmail.com.
[Ti] Título:Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease.
[So] Source:Anticancer Res;37(12):7005-7010, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: The aim of this study was to investigate the treatment outcomes and toxicities in patients with liver disease treated by Stereotactic Body Radiation Therapy (SBRT). PATIENTS AND METHODS: From 2007 to 2016, 43 patients with 58 lesions (6 primary and 37 metastatic liver tumors) were treated with SBRT. RESULTS: Local Control was reached in 47 out of 58 (81%) treated lesions with 12 and 24-month rates of 81% and 74% respectively. The progression-free survival at 12 and 24 months was 42% and 36%, respectively. The disease specific survival at 12 and 24 months was 74% and 46% respectively. Median overall survival (OS) was 20 months and the rates of OS were 74% and 46% at 12 and 24 months respectively. Toxicity was very low consisting mainly of Grade 1 and 2. CONCLUSION: SBRT provides good local control for both primary and metastatic liver lesions, with minimal toxicity.
[Mh] Termos MeSH primário: Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/radioterapia
Radiocirurgia/métodos
Dosagem Radioterapêutica
[Mh] Termos MeSH secundário: Dor Abdominal/etiologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Diarreia/etiologia
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Náusea/etiologia
Metástase Neoplásica
Radiocirurgia/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  10 / 14127 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29187483
[Au] Autor:Sento S; Kitamura N; Yamamoto T; Nakashiro K; Hamakawa H; Ibaragi S; Sasaki A; Takamaru N; Miyamoto Y; Kodani I; Ryoke K; Mishima K; Ueyama Y; ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU
[Ad] Endereço:Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Japan shinya-sento@kochi-u.ac.jp.
[Ti] Título:Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
[So] Source:Anticancer Res;37(12):6977-6981, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients. PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy. RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC. CONCLUSION: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Isoquinolinas/uso terapêutico
Neoplasias Bucais/tratamento farmacológico
Náusea/prevenção & controle
Quinuclidinas/uso terapêutico
Vômito/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intravenosa
Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Quimioterapia Combinada
Feminino
Seres Humanos
Isoquinolinas/administração & dosagem
Masculino
Meia-Idade
Náusea/induzido quimicamente
Quinuclidinas/administração & dosagem
Antagonistas da Serotonina/administração & dosagem
Antagonistas da Serotonina/uso terapêutico
Resultado do Tratamento
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Isoquinolines); 0 (Quinuclidines); 0 (Serotonin Antagonists); 5D06587D6R (palonosetron); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE



página 1 de 1413 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde